

| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 描述 | Poliumoside is a natural compound which exhibit significant inhibition of advanced glycation end product formation with IC50 values of 4.6-25.7 μM |
| Concentration | Treated Time | Description | References | |
| Human microvascular endothelial cells (MVECs) | 30 micromolar | 24 hours | Poliumoside did not activate the Nrf2 cell defense pathway, did not induce expression of Nrf2 target genes, and did not promote nuclear translocation of Nrf2. | J Ethnopharmacol. 2016 Dec 4;193:397-407 |
| A549 cells | 10, 20, 40 µM | 24 hours | To evaluate the protective effects of POL against TNF-α-induced damage in A549 cells. Results showed that POL dose-dependently attenuated TNF-α-induced IL-1β, IL-6, and IL-8 production, cell apoptosis, the expression of apoptosis-related genes (Caspase 3, Caspase 8, and Caspase 9), and ROS activity. | Front Pharmacol. 2021 Jul 7;12:693983 |
| Administration | Dosage | Frequency | Description | References | ||
| Mice | Spinal cord injury model | Intraperitoneal injection | 20 or 40 mg/kg | Once daily for 1 week | To evaluate the therapeutic effects of Poliumoside on spinal cord injury, results showed that Poliumoside improved neural pathology and motor function recovery. | Theranostics. 2025 Mar 18;15(9):4188-4211 |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
1.30mL 0.26mL 0.13mL |
6.49mL 1.30mL 0.65mL |
12.97mL 2.59mL 1.30mL |
|
| CAS号 | 94079-81-9 |
| 分子式 | C35H46O19 |
| 分子量 | 770.73 |
| SMILES Code | O(C(/C=C/C1=CC(O)=C(O)C=C1)=O)[C@H]2[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](O)[C@H](OCCC4=CC(O)=C(O)C=C4)O[C@@H]2CO[C@H]5[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O5 |
| MDL No. | MFCD23160017 |
| 别名 | |
| 运输 | 蓝冰 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Inert atmosphere, 2-8°C |
| 溶解方案 |
DMSO: 105 mg/mL(136.23 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO H2O: 50 mg/mL(64.87 mM),配合低频超声助溶 无水乙醇: 45 mg/mL(58.39 mM),配合低频超声助溶,注意:无水乙醇开封后,易挥发,也会吸收空气中的水分,导致溶解能力下降,请避免使用开封较久的乙醇 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1